MyBody-X angle on DNA Test Basis

The MyBody-X DNA Test Basis analyzes selected genetic variants, typically covering pharmacogenetics (e.g., CYP2D6), inflammatory tendency (IL1B), and some GWAS associations (e.g., FTO rs9939609 for weight regulation). The evidence is mixed: CYP2D6 has strong human genetic guidelines (e.g., CPIC) affecting drug metabolism. IL1B and FTO have moderate to GWAS-level evidence, but effect sizes are small and not clinically predictive. Other markers like COL1A1 (collagen) or GPX1 (antioxidants) rely on mechanistic or lab studies without robust human trials for skin aging. Importantly, this test is not diagnostic. Results should never lead to self-medication or therapy changes. Fatigue, low libido, or other symptoms require medical evaluation. MyBody-X provides risk estimates, but the clinical relevance of many SNPs is limited. The hormone tests (thyroid) complement the picture but are also single time-point snapshots. Overall, the test offers useful insights, especially for drug tolerance, but with clear limitations for lifestyle and prevention claims.